Clinical trials: Bladder Carcinoma
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Trial name
- NCT03744793
- Testing
- Avelumab, Pemetrexed
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Ta/T1
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
In this phase 4 trial (000439), subjects with NMIBC CIS (± high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction…
- Conditions
- Bladder Cancer, Ta/T1, CIS
- Trial name
- ABLE-42 (NCT06390111)
- Testing
- nadofaragene firadenovec
- Where
- 2 sites in United States
- Sponsor
- Ferring Pharmaceuticals
Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.
- Conditions
- Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer
- Trial name
- NCT06443944
- Testing
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Where
- 27 sites in United States
- Sponsor
- CG Oncology, Inc.
Non-muscle Invasive Bladder Cancer
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in adjuvant/salvage treatment of HER2 positive high-risk non-muscle-invasive bladder cancer.
- Trial name
- NCT05996952
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 77 people
- Sponsor
- West China Hospital
Bladder Cancer
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01410565
- Testing
- Apaziquone
- Where
- 47 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Bladder Cancer
Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer
The principal objective of this study consists in the assessment of Immunogenic Cell Death (ICD) induction in neoplastic tissues derived from bladder cancer patients treated ex vivo with Mitomycin C (MMC).
- Trial name
- ICH-MIM-01 (NCT04256616)
- Testing
- This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Bladder Cancer
The Accuracy of Optic Biopsies Versus Conventional Biopsies for the Diagnosis of Superficial Bladder Neoplasia
This study evaluates the accuracy of Confocal Laser Endomicroscopy (CLE) in the diagnostic of non-invasive flat and exophytic bladder neoplasia. CLE results are compared to histopathology results.
- Trial name
- NCT02841904
- Testing
- Confocal LASER Endomicroscopy
- Where
- Denmark
- Volunteers
- 189 people
- Sponsor
- Herlev Hospital
Lower Urinary Tract Symptoms, Intravenous Drug Usage
JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer
To identify the effects of JING SI HERBAL TEA in the treatment of lower urinary tract symptoms after intravesical therapy in patients with bladder cancer.
- Conditions
- Lower Urinary Tract Symptoms, Intravenous Drug Usage, Bladder Cancer, Herbal Interaction
- Trial name
- NCT05739071
- Testing
- JING SI HERBAL TEA
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Bladder Tumors
Laser Treatment of Bladder Tumors in the Outpatient Department
Primary Objective: To show that small pTa bladder tumors can be removed with diode laser in an outpatient department. Secondary Objective: To evaluate the patients' symptoms during and after the laser TURBT.
- Trial name
- NCT02659332
- Testing
- TURBT
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Gregers G Hermann
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Bladder Cancer, Radical Cystectomy
CLEAR Care Companion Application
Hospital readmissions are common after major cancer surgery, leading to poorer patient outcomes, increased mortality and additional costs.
- Trial name
- NCT05578898
- Testing
- CLEAR Care Companion (CC) application
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Ureter Cancer, Urethral Cancer
- Trial name
- NCT01191892
- Testing
- carboplatin, gemcitabine hydrochloride, vandetanib
- Where
- 21 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Cardiff University
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Muscle Invasive Bladder Cancer
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with…
- Trial name
- NCT06929286
- Testing
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel
- Where
- 9 sites in United States
- Volunteers
- 125 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
This study is looking at the effects of Sirolimus (Rapamycin) on BCG-specific immunity during treatment of non-muscle invasive bladder cancer (NMIBC) with maintenance BCG.
- Trial name
- NCT02753309
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Muscle Invasive Bladder Cancer
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive…
- Trial name
- TEP-Vessie (NCT04053101)
- Testing
- PET CT
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Bergonié
Neoplasm, Ureter, Neoplasm, Bladder
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
This clinical trial is designed to compare the effect of single postoperative intravesical chemotherapy instillation versus maintenance therapy on reducing bladder cancer recurrence after surgery for UTUC.
- Trial name
- NCT02438865
- Testing
- Immediate instillation of intravesical chemotherapy-Epirubicin-, Maintainance therapy of intravesical chemotherapy-Epirubicin-
- Where
- Egypt
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Recurrent Bladder Carcinoma, Stage II Bladder Cancer
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer.
- Conditions
- Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Trial name
- NCT01938573
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Washington